AKTX - Akari Therapeutics, Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Revenue - - - -
Cost of Revenue - - - -
Gross Profit - - - -
Operating Expenses
Research Development 11,795.376 23,285.279 17,306.001 5,799.076
Selling General and Administrative 10,896.158 11,798.91 9,940.557 5,502.214
Non Recurring - - - -
Others - - - -
Total Operating Expenses 22,691.534 35,084.189 27,246.558 11,301.29
Operating Income or Loss -22,691.534 -35,084.189 -27,246.558 -11,301.29
Income from Continuing Operations
Total Other Income/Expenses Net 6,224.754 -315.068 9,105.561 -34,016.242
Earnings Before Interest and Taxes -22,691.534 -35,084.189 -27,246.558 -11,301.29
Interest Expense - - - -3,053.948
Income Before Tax -16,466.78 -35,399.257 -18,140.997 -45,317.532
Income Tax Expense - - - -
Minority Interest - - - -
Net Income From Continuing Ops -16,466.78 -35,399.257 -18,140.997 -45,317.532
Non-recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Changes - - - -
Other Items - - - -
Net Income
Net Income -16,466.78 -35,399.257 -18,140.997 -45,317.532
Preferred Stock And Other Adjustments - - - -
Net Income Applicable To Common Shares -16,466.78 -35,399.257 -18,140.997 -45,317.532